Novel Genetic Loci Associated with Osteoarthritis in Multi-Ancestry Analyses in 484,374 Participants from MVP and the UK Biobank

Competing Interest Statement

Jasvinder A. Singh has received consultant fees from Crealta/Horizon, Medisys, Fidia, UBM LLC, Trio health, Medscape, WebMD, PK Med, Two labs Inc., Adept Field Solutions, Clinical Care options, Clearview healthcare partners, Putnam associates, Focus forward, Navigant consulting, Spherix, Practice Point communications, the National Institutes of Health and the American College of Rheumatology. Jasvinder A. Singh has received institutional research support from Zimmer Biomet Holdings. Jasvinder A. Singh received food and beverage payments from Intuitive Surgical Inc./Philips Electronics North America. Jasvinder A. Singh owns stock options in TPT Global Tech, Vaxart pharmaceuticals, Atyu biopharma, Adaptimmune Therapeutics, GeoVax Labs, Pieris Pharmaceuticals, Enzolytics Inc., Seres Therapeutics, Tonix Pharmaceuticals Holding Corp., and Charlottes Web Holdings, Inc. Jasvinder A. Singh previously owned stock options in Amarin, Viking and Moderna pharmaceuticals. Jasvinder A. Singh is on the speakers bureau of Simply Speaking. Jasvinder A. Singh is a member of the executive of Outcomes Measures in Rheumatology (OMERACT), an organization that develops outcome measures in rheumatology and receives arms-length funding from 12 companies. Jasvinder A. Singh serves on the FDA Arthritis Advisory Committee. Jasvinder A. Singh is the chair of the Veterans Affairs Rheumatology Field Advisory Committee. Jasvinder A. Singh is the editor and the Director of the University of Alabama at Birmingham (UAB) Cochrane Musculoskeletal Group Satellite Center on Network Meta-analysis. Jasvinder A. Singh previously served as a member of the following committees: member, the American College of Rheumatology (ACR) Annual Meeting Planning Committee (AMPC) and Quality of Care Committees, the Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and the co-chair of the ACR Criteria and Response Criteria subcommittee.

Funding Statement

This research is based on data from the Million Veteran Program, Office of Research and Development, Veterans Health Administration, and was supported by award #I01RX002745. This publication does not represent the views of the Department of Veteran Affairs or the United States Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The work described in this manuscript received ethical and study protocol approval from the Veterans Affairs Central Institutional Review Board as well as the University of Alabama at Birmingham in accordance with the principles outlined in the Declaration of Helsinki. UK Biobank data was analyzed under approved access via proposal #30350.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes